annb0t
Top 20
MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company)Â today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University Vienna. (PRNewsfoto/Telix Pharmaceuticals Limited)
Dedicaid's core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDS...
>>> Read more: Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid
Dedicaid's core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDS...
>>> Read more: Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid